Medicamen Biotech Ratios

Medicamen Biotech Ltd Ratios

The Medicamen Biotech Ltd Ratios page provides a complete fundamental analysis of Medicamen Biotech Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Medicamen Biotech Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Medicamen Biotech Ltd (NSE: MEDICAMEQ, BSE: 531146) is currently trading at ₹223.30, with a market capitalization of ₹3.05B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Medicamen Biotech Ltd remains a key stock for fundamental analysis using Medicamen Biotech Ltd Ratios.

Medicamen Biotech Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Medicamen Biotech Ltd P/E ratio currently stands at 86.16, making it one of the most tracked metrics in Medicamen Biotech Ltd Ratios.

Historically, the Medicamen Biotech Ltd P/E ratio has shown strong fluctuations:

• 2024: 86.16
• 2023: 44.37
• 2022: 55.01
• 2021: 52.79
• 2020: 53.78

The rising Medicamen Biotech Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Medicamen Biotech Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.87.

Historical P/B trend:

• 2024: 2.87
• 2023: 2.34
• 2022: 4.29
• 2021: 5.37

Medicamen Biotech Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Medicamen Biotech Ltd P/S ratio currently stands at 3.77, an important part of Medicamen Biotech Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.77
• 2023: 2.70
• 2022: 5.80
• 2021: 6.81

The rising Medicamen Biotech Ltd P/S ratio indicates improved revenue valuation by investors.

Medicamen Biotech Ltd Price to Cash Flow Ratio (P/CF)

The Medicamen Biotech Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Medicamen Biotech Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 276.51
• 2020: 55

The declining Medicamen Biotech Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Medicamen Biotech Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Medicamen Biotech Ltd EV currently stands at ₹6.42B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 6.42B
• 2023: 5.01B
• 2022: 8.21B
• 2021: 8.08B

Medicamen Biotech Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Medicamen Biotech Ltd EV/EBITDA ratio is currently 43.59, a key metric in Medicamen Biotech Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 43.59
• 2023: 20.22
• 2022: 32.19
• 2021: 33.02

Higher Medicamen Biotech Ltd EV/EBITDA suggests premium valuation.

Medicamen Biotech Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Medicamen Biotech Ltd D/E ratio is currently 0.16, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.16
• 2023: 0.15
• 2022: 0.13
• 2021: 0.18

Medicamen Biotech Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Medicamen Biotech Ltd ROE currently stands at 3.38%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 3.38
• 2023: 5.46
• 2022: 8.73
• 2021: 10.67

Declining ROE indicates pressure on profitability.

Medicamen Biotech Ltd Ratios Analysis Summary

The Medicamen Biotech Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Medicamen Biotech Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Medicamen Biotech Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.